Absci (ABSI) Q1 2026 Earnings Call Summary
Absci reported $200 thousand in revenue for the quarter, driven by progress in partnered programs. R&D expenses increased to $19.3 million due to internal program investments and ABS-201 development, while SG&A costs decreased slightly. The company ended Q1 with $125.7 million in cash and expects sufficient funding through 2028.
Tickers: $ABSI
Topics: cash_balance clinical_progress expenses revenue